Advanced search
Publication Cover
mAbs Volume 15, 2023 - Issue 1
Submit an article Journal homepage
2,441
Views
1
CrossRef citations to date
0
Altmetric
Report

GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery

Loes van Schiea UGent Department of Biochemistry and microbiology, Ghent University, Ghent, Belgium;b VIB-UGent Center for Medical Biotechnology, Ghent, BelgiumORCID Iconhttps://orcid.org/0000-0003-2588-9750View further author information
ORCID Icon,
Wander Van Breedama UGent Department of Biochemistry and microbiology, Ghent University, Ghent, Belgium;b VIB-UGent Center for Medical Biotechnology, Ghent, BelgiumORCID Iconhttps://orcid.org/0000-0001-7755-988XView further author information
ORCID Icon,
Charlotte Roelsa UGent Department of Biochemistry and microbiology, Ghent University, Ghent, Belgium;b VIB-UGent Center for Medical Biotechnology, Ghent, BelgiumORCID Iconhttps://orcid.org/0000-0001-9659-5106View further author information
ORCID Icon,
Bert Schepensa UGent Department of Biochemistry and microbiology, Ghent University, Ghent, Belgium;b VIB-UGent Center for Medical Biotechnology, Ghent, BelgiumORCID Iconhttps://orcid.org/0000-0002-2028-1984View further author information
ORCID Icon,
Martin Frankc Biognos AB, Göteborg, SwedenORCID Iconhttps://orcid.org/0000-0002-1006-6746View further author information
ORCID Icon,
Ahmad Reza Mehdipourd UGent Center for Molecular Modeling, Ghent University, Ghent, BelgiumORCID Iconhttps://orcid.org/0000-0002-0193-3334View further author information
ORCID Icon,
Bram Laukensa UGent Department of Biochemistry and microbiology, Ghent University, Ghent, Belgium;b VIB-UGent Center for Medical Biotechnology, Ghent, BelgiumView further author information
,
Wim Nerinckxa UGent Department of Biochemistry and microbiology, Ghent University, Ghent, Belgium;b VIB-UGent Center for Medical Biotechnology, Ghent, BelgiumORCID Iconhttps://orcid.org/0000-0002-6563-8342View further author information
ORCID Icon,
Francis Santensa UGent Department of Biochemistry and microbiology, Ghent University, Ghent, Belgium;b VIB-UGent Center for Medical Biotechnology, Ghent, BelgiumORCID Iconhttps://orcid.org/0000-0001-9521-9846View further author information
ORCID Icon,
Simon Devosa UGent Department of Biochemistry and microbiology, Ghent University, Ghent, Belgium;b VIB-UGent Center for Medical Biotechnology, Ghent, BelgiumORCID Iconhttps://orcid.org/0000-0002-0623-433XView further author information
ORCID Icon,
Iebe Rosseya UGent Department of Biochemistry and microbiology, Ghent University, Ghent, Belgium;b VIB-UGent Center for Medical Biotechnology, Ghent, BelgiumORCID Iconhttps://orcid.org/0000-0002-0795-972XView further author information
ORCID Icon,
Karel Thoofta UGent Department of Biochemistry and microbiology, Ghent University, Ghent, Belgium;b VIB-UGent Center for Medical Biotechnology, Ghent, Belgium;e UGent Department of Organic and Macromolecular Chemistry, Ghent University, Ghent, BelgiumView further author information
,
Sandrine Vanmarckea UGent Department of Biochemistry and microbiology, Ghent University, Ghent, Belgium;b VIB-UGent Center for Medical Biotechnology, Ghent, BelgiumORCID Iconhttps://orcid.org/0000-0002-0955-7556View further author information
ORCID Icon,
Annelies Van Heckea UGent Department of Biochemistry and microbiology, Ghent University, Ghent, Belgium;b VIB-UGent Center for Medical Biotechnology, Ghent, BelgiumORCID Iconhttps://orcid.org/0000-0002-3010-8034View further author information
ORCID Icon,
Xavier Saelensa UGent Department of Biochemistry and microbiology, Ghent University, Ghent, Belgium;b VIB-UGent Center for Medical Biotechnology, Ghent, BelgiumView further author information
&
Nico Callewaerta UGent Department of Biochemistry and microbiology, Ghent University, Ghent, Belgium;b VIB-UGent Center for Medical Biotechnology, Ghent, BelgiumCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2069-6917View further author information
ORCID Icon show all
Article: 2210709 | Received 30 Jan 2023, Accepted 02 May 2023, Published online: 21 May 2023

References

  • Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers EB, Songa N, Bendahman R, Hammers R. Naturally occurring antibodies devoid of light chains. Nature. 1993;363(6428):446–16. doi:10.1038/363446a0.
  • Desmyter A, Transue TR, Ghahroudi MA, Dao Thi M-H, Poortmans F, Hamers R, Muyldermans S, Wyns L. Crystal structure of a camel single-domain V H antibody fragment in complex with lysozyme. Nat Struct Biol. 1996;3(9):803–11. doi:10.1038/nsb0996-803.
  • Harmsen MM, Van Solt CB, Fijten HPD. Enhancement of toxin- and virus-neutralizing capacity of single-domain antibody fragments by N-glycosylation. Appl Microbiol Biotechnol. 2009;84(6):1087–94. doi:10.1007/s00253-009-2029-1.
  • Baskin JM, Bertozzi CR. Bioorthogonal click chemistry: covalent labeling in living systems. QSAR Comb Sci. 2007;26(11–12):1211–19. doi:10.1002/qsar.200740086.
  • Jacobs PP, Geysens S, Vervecken W, Contreras R, Callewaert N. Engineering complex-type N-glycosylation in Pichia pastoris using GlycoSwitch technology. Nat Protoc. 2009;4(1):58–70. doi:10.1038/nprot.2008.213.
  • Meuris L, Santens F, Elson G, Festjens N, Boone M, Dos Santos A, Devos S, Rousseau F, Plets E, Houthuys E, et al. GlycoDelete engineering of mammalian cells simplifies N-glycosylation of recombinant proteins. Nat Biotechnol. 2014;32(5):485–89. doi:10.1038/nbt.2885.
  • Van Breedam W, Thooft K, Santens F, Vanmarcke S, Wyseure E, Laukens B, Van Moer B, Nerinckx W, Devos S, Madder A, et al. GlyConnect: a glycan-based conjugation extension of the GlycoDelete technolog. bioRxiv. 2021. doi:10.1101/2021.06.02.446789v2.
  • Thooft K, Breedam WV, Santens F, Wyseure E, Vanmarcke S, Devos S, Callewaert N, Madder A. GlyConnect-Ugi: site-selective, multi-component glycoprotein conjugations through GlycoDelete expressed glycans. Org Biomol Chem. 2022;20(2):464–71. doi:10.1039/D1OB02299G.
  • Shaaltiel Y, Bartfeld D, Hashmueli S, Baum G, Brill‐almon E, Galili G, Dym O, Boldin‐adamsky SA, Silman I, Sussman JL, et al. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher’s disease using a plant cell system. Plant Biotechnol J. 2007;5(5):579–90. doi:10.1111/j.1467-7652.2007.00263.x.
  • Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, Cooper PA, Varughese S, Giraldo P, Petakov M, Tan ES, Chertkoff R. Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase. Blood Cells Mol Dis. 2018;68:163–72. doi:10.1016/j.bcmd.2016.10.005.
  • Sycz G, Venanzio GD, Distel JS, Sartorio MG, Le N-H, Scott NE, Beatty WL, Feldman MF, Weiss DS. Modern Acinetobacter baumannii clinical isolates replicate inside spacious vacuoles and egress from macrophages. PLoS Pathog. 2021;17(8):e1009802. doi:10.1371/journal.ppat.1009802.
  • Kumar PV, Asthana A, Dutta T, Jain NK. Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers. J Drug Target. 2006;14(8):546–56. doi:10.1080/10611860600825159.
  • Azad AK, Rajaram MVS, Schlesinger LS. Exploitation of the macrophage mannose receptor (CD206) in infectious disease diagnostics and therapeutics. J Cytol Mol Biol. 2014;1:1–5.
  • Vieira ACC, Chaves LL, Pinheiro M, Lima SAC, Ferreira D, Sarmento B, Reis S. Mannosylated solid lipid nanoparticles for the selective delivery of rifampicin to macrophages. Artif Cells Nanomedicine Biotechnol. 2018;46(sup1):653–63. doi:10.1080/21691401.2018.1434186.
  • Lehar SM, Pillow T, Xu M, Staben L, Kajihara KK, Vandlen R, DePalatis L, Raab H, Hazenbos WL, Morisaki JH, et al. Novel antibody–antibiotic conjugate eliminates intracellular S. aureus. Nature. 2015;527(7578):323–28. doi:10.1038/nature16057.
  • Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335–46. doi:10.1056/NEJMoa1806311.
  • Honegger A, Plückthun A. Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool. J Mol Biol. 2001;309(3):657–70. doi:10.1006/jmbi.2001.4662.
  • Kubala MH, Kovtun O, Alexandrov K, Collins BM. Structural and thermodynamic analysis of the GFP: gFP-nanobody complex. Protein Sci. 2010;19(12):2389–401. doi:10.1002/pro.519.
  • Kaup M, Saul VV, Lusch A, Dörsing J, Blanchard V, Tauber R, Berger M. Construction and analysis of a novel peptide tag containing an unnatural N-glycosylation site. FEBS Lett. 2011;585(14):2372–76. doi:10.1016/j.febslet.2011.06.010.
  • Wong CH Glycan-binding specificities of CLEC2, BDCA2, Langerin, DEC205, Endo180, MMR and DCAL-1. La Jolla (CA): functional Glycomics Gateway investigator, for the Consortium for Functional Glycomics; 2006[accessed 2020 Sep 9]. http://www.functionalglycomics.org/glycomics/HServlet?operation=view&sideMenu=no&psId=primscreen_PA_v2_411_03292006.
  • Bañó-Polo M, Baldin F, Tamborero S, Marti-Renom MA, Mingarro I. N-glycosylation efficiency is determined by the distance to the C-terminus and the amino acid preceding an Asn-Ser-Thr sequon. Protein Sci. 2011;20(1):179–86. doi:10.1002/pro.551.
  • Laukens B, Jacobs PP, Geysens K, Martins J, De Wachter C, Ameloot P, Morelle W, Haustraete J, Renauld J-C, Samyn B, et al. Off-target glycans encountered along the synthetic biology route toward humanized N-glycans in Pichia pastoris. Biotechnol Bioeng. 2020;117(8):2479–88. doi:10.1002/bit.27375.
  • Mille C, Bobrowicz P, Trinel P-A, Li H, Maes E, Guerardel Y, Fradin C, Martínez-Esparza M, Davidson RC, Janbon G, et al. Identification of a new family of genes involved in β-1,2-mannosylation of glycans in pichia pastoris and Candida albicans. J Biol Chem. 2008;283(15):9724–36. doi:10.1074/jbc.M708825200.
  • Hopkins D, Gomathinayagam S, Rittenhour AM, Du M, Hoyt E, Karaveg K, Mitchell T, Nett JH, Sharkey NJ, Stadheim TA, et al. Elimination of -mannose glycan structures in Pichia pastoris. Glycobiology. 2011;21(12):1616–26. doi:10.1093/glycob/cwr108.
  • Gecht M, von Bülow S, Penet C, Hummer G, Hanus C, Sikora M. GlycoSHIELD: a versatile pipeline to assess glycan impact on protein structures. bioRxiv. 2021. doi:10.1101/2021.08.04.455134.
  • M-C L, Aulabaugh A, Jin G, Cowling R, Bard J, Malamas M, Ellestad G. Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal Biochem. 2004;332(1):153–59. doi:10.1016/j.ab.2004.04.031.
  • Nguyen VK, Hamers R, Wyns L, Muyldermans S. Camel heavy-chain antibodies: diverse germline VHH and specific mechanisms enlarge the antigen-binding repertoire. Embo J. 2000;19(5):921–30. doi:10.1093/emboj/19.5.921.
  • Feng H, Galen JE, Chen K, Zhu Y, inventors; University of Maryland, Baltimore, assignee. Yeast-Based Immunotherapy Against Clostridium Difficile Infection. World Intellectual Property Organization WO/2017/066468 A1; 2017.
  • Yang Z, Schmidt D, Liu W, Li S, Shi L, Sheng J, Chen K, Yu H, Tremblay JM, Chen X, et al. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant clostridium difficile infection in mice. J Infect Dis. 2014;210(6):964–72. doi:10.1093/infdis/jiu196.
  • Buyse M-A, Boutton C, inventors; Ablynx Nv, assignee. Glycosylated immunoglobulin single variable domains. World Intellectual Property Organization WO/2016/150845 A1; 2016.
  • Koury MJ. Sugar coating extends half-lives and improves effectiveness of cytokine hormones. Trends Biotechnol. 2003;21(11):462–64. doi:10.1016/j.tibtech.2003.09.002.
  • Van Delft FL, Van Geel R, Wijdeven MA, inventors; Synaffix b.v., assignee. Modified Antibody, Antibody-Conjugate and Process for the Preparation Thereof. World Intellectual Property Organization WO/2014/065661 A1; 2014.
  • Van Delft FL, Van Geel R, Wijdeven MA, inventors; Synaffix B.V., assignee. Modified glycoprotein, protein-conjugate and process for the preparation thereof. World Intellectual Property Organization WO/2015/057064 A1; 2015.
  • Van Delft FL, Van Geel R, Wijdeven MA, Verkade JMM, Heesbeen R, inventors; Synaffix b.v., assignee. Glyco-engineered Antibody, Antibody-conjugate and methods for their preparation. World Intellectual Property Organization WO/2015/057065 A1; 2015.
  • Schoonooghe S, Kaigorodov V, Zawisza M, Dumolyn C, Haustraete J, Grooten J, Mertens N. Efficient production of human bivalent and trivalent anti-MUC1 Fab-scFv antibodies in Pichia pastoris. BMC Biotechnol. 2009;9(1):70. doi:10.1186/1472-6750-9-70.
  • Rossey I, Gilman MSA, Kabeche SC, Sedeyn K, Wrapp D, Kanekiyo M, Chen M, Mas V, Spitaels J, Melero JA, et al. Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state. Nat Commun. 2017;8(1):14158. doi:10.1038/ncomms14158.
  • Lee ME, DeLoache WC, Cervantes B, Dueber JE. A highly characterized yeast toolkit for modular, multipart assembly. ACS Synth Biol. 2015;4(9):975–86. doi:10.1021/sb500366v.
  • Van Herpe D, Vanluchene R, Vandewalle K, Vanmarcke S, Wyseure E, Van Moer B, Eeckhaut H, Fijalkowska D, Grootaert H, Lonigro C, et al. Openpichia: building a free-to-operate Komagataella phaffii protein expression toolkit. bioRxiv. 2022. doi:10.1101/2022.12.13.519130.
  • Kurtzman CP. Biotechnological strains of Komagataella (Pichia) pastoris are Komagataella phaffii as determined from multigene sequence analysis. J Ind Microbiol Biotechnol. 2009;36(11):1435. doi:10.1007/s10295-009-0638-4.
  • Fairhead M, Howarth M. Site-specific biotinylation of purified proteins using BirA. Methods Mol Biol Clifton NJ. 2015;1266:171–84.
  • Stals I, Samyn B, Sergeant K, White T, Hoorelbeke K, Coorevits A, Devreese B, Claeyssens M, Piens K. Identification of a gene coding for a deglycosylating enzyme in Hypocrea jecorina. FEMS Microbiol Lett. 2010;303(1):9–17. doi:10.1111/j.1574-6968.2009.01849.x.
  • Laroy W, Contreras R, Callewaert N. Glycome mapping on DNA sequencing equipment. Nat Protoc. 2006;1(1):397–405. doi:10.1038/nprot.2006.60.
  • Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, Lindahl E. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1–2:19–25. doi:10.1016/j.softx.2015.06.001.
  • Krieger E, Vriend G. YASARA View—molecular graphics for all devices—from smartphones to workstations. Bioinforma Oxf Engl. 2014;30(20):2981–82. doi:10.1093/bioinformatics/btu426.
  • Krieger E, Vriend G. New ways to boost molecular dynamics simulations. J Comput Chem. 2015;36(13):996–1007. doi:10.1002/jcc.23899.
  • Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C. Ff14sb: improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput. 2015;11(8):3696–713. doi:10.1021/acs.jctc.5b00255.
  • Kirschner KN, Yongye AB, Tschampel SM, González-Outeiriño J, Daniels CR, Foley BL, Woods RJ. GLYCAM06: a generalizable biomolecular force field. Carbohydrates. J Comput Chem. 2008;29(4):622–55. doi:10.1002/jcc.20820.
  • van Schie L, Van Breedam W, Roels C, Schepens B, Frank M, Mehdipour AR, Laukens B, Nerinckx W, Santens F, Devos S, et al. GlycoVHH: introducing N-glycans on the camelid VHH antibody scaffold - Optimal sites and use for macrophage delivery. bioRxiv. 2022. doi:10.1101/2022.04.25.489312.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.